

March 23, 2020

Oncology Services and Treatments Amid COVID-19 Environment

In an effort to protect patients and staff amid the ongoing COVID-19 pandemic, and the recent [Executive Order from Governor Whitmer](#), the Oncology Services team is actively reviewing all scheduled visits and diagnostic testing.

Based upon clinical criteria established by our team of oncology specialists, prioritization of patients are reviewed with the following being implemented:

- Infusion Services:
 - Oncology patients and related treatments will continue
 - Pregnancy related hydration for electrolyte infusions will continue
 - GI, Neurological, Nephrology, and Rheumatologic treatments will continue
 - Blood and platelet transfusions that follow the MHC Adult Blood Product Transfusion Guidelines will continue
 - Osteoporosis treatments who have not yet completed lab analysis will be rescheduled into the future
 - Referring providers will be contacted on a case by case basis to determine if the treatment is required to “*preserve the health and safety of the patient*” (example: allergy, asthma, iron)
- Surgical and Gynecologic Oncology: Patients in whom a delay in surgery would significantly alter the patient’s prognosis will continue.
- Medical Oncology: Given the current concern of COVID-19 exposure, we will identify patients best suited for a virtual or telephonic visit, in place of an in-person encounter. New consults are reviewed by the providers on a case-by-case basis.
- Radiation Oncology:
 - Patients currently receiving radiation treatments will continue
 - Given the current concern of COVID-19 exposure, we will identify patients best suited for a virtual or telephonic visit, in place of an in-person encounter. New consults are reviewed by the providers on a case by case basis.
- Radiologic diagnostic tests:
 - PET/CT: continue to perform if required for treatment/management decisions
 - Pre-treatment prostate MR: continue perform if required for treatment planning
 - Repeat/follow up imaging – oncologists discretion based on NCCN guidelines

If you have a question regarding how to handle a specific case, feel free to contact us at **231-392-8400** and we put you in contact with the appropriate infusion clinics or with one of our providers. We appreciate your patience as we all work through this challenging time together.

Regards,

David Gordon, MD
Physician Chief, Oncology Service Line
Munson Healthcare

Kathleen LaRaia, MS
Executive Director, Oncology Service Line
Munson HealthCare